Published by Iain Gilbert on 28th October 2025
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Koselugo asset has been approved for usage in the European Union for the rare, progressive, genetic condition, plexiform neurofibromas, in adults with neurofibromatosis type 1.
URL: http://www.digitallook.com/dl/news/story/35452357/...